Find Radalbuvir manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

API Suppliers

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

0 DRUGS IN DEVELOPMENT

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Gs-9669, Radalbuvir [inn], 273k4v0spc, 2-thiophenecarboxylic acid, 5-(3,3-dimethyl-1-butyn-1-yl)-3-((cis-4-hydroxy-4-((((3s)-tetrahydro-3-furanyl)oxy)methyl)cyclohexyl)(((1r)-4-methyl-3-cyclohexen-1-yl)carbonyl)amino)-, 1314795-11-3, Unii-273k4v0spc
Molecular Formula
C30H41NO6S
Molecular Weight
543.7  g/mol
InChI Key
MUICUPWICXUNRS-UVXQUXCMSA-N
FDA UNII
273K4V0SPC

Radalbuvir
Radalbuvir has been used in trials studying the treatment of Chronic Hepatitis C, Chronic HCV Infection, and Chronic Hepatitis C Infection.
1 2D Structure

Radalbuvir

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
5-(3,3-dimethylbut-1-ynyl)-3-[[4-hydroxy-4-[[(3S)-oxolan-3-yl]oxymethyl]cyclohexyl]-[(1R)-4-methylcyclohex-3-ene-1-carbonyl]amino]thiophene-2-carboxylic acid
2.1.2 InChI
InChI=1S/C30H41NO6S/c1-20-5-7-21(8-6-20)27(32)31(25-17-24(11-13-29(2,3)4)38-26(25)28(33)34)22-9-14-30(35,15-10-22)19-37-23-12-16-36-18-23/h5,17,21-23,35H,6-10,12,14-16,18-19H2,1-4H3,(H,33,34)/t21-,22?,23-,30?/m0/s1
2.1.3 InChI Key
MUICUPWICXUNRS-UVXQUXCMSA-N
2.1.4 Canonical SMILES
CC1=CCC(CC1)C(=O)N(C2CCC(CC2)(COC3CCOC3)O)C4=C(SC(=C4)C#CC(C)(C)C)C(=O)O
2.1.5 Isomeric SMILES
CC1=CC[C@@H](CC1)C(=O)N(C2CCC(CC2)(CO[C@H]3CCOC3)O)C4=C(SC(=C4)C#CC(C)(C)C)C(=O)O
2.2 Other Identifiers
2.2.1 UNII
273K4V0SPC
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Gs-9669

2.3.2 Depositor-Supplied Synonyms

1. Gs-9669

2. Radalbuvir [inn]

3. 273k4v0spc

4. 2-thiophenecarboxylic Acid, 5-(3,3-dimethyl-1-butyn-1-yl)-3-((cis-4-hydroxy-4-((((3s)-tetrahydro-3-furanyl)oxy)methyl)cyclohexyl)(((1r)-4-methyl-3-cyclohexen-1-yl)carbonyl)amino)-

5. 1314795-11-3

6. Unii-273k4v0spc

7. Radalbuvir [who-dd]

8. Chembl3121539

9. Schembl12444696

10. Schembl15252929

11. Schembl15252930

12. Schembl19607380

13. Dtxsid401028100

14. Db12065

15. Hy-16750

16. Cs-0012349

17. Q21098892

18. 5-(3,3-dimethylbut-1-ynyl)-3-[[4-hydroxy-4-[[(3s)-tetrahydrofuran-3-yl]oxymethyl]cyclohexyl]-[(1r)-4-methylcyclohex-3-ene-1-carbonyl]amino]thiophene-2-carboxylic Acid

2.4 Create Date
2011-08-01
3 Chemical and Physical Properties
Molecular Weight 543.7 g/mol
Molecular Formula C30H41NO6S
XLogP34.7
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count7
Rotatable Bond Count9
Exact Mass g/mol
Monoisotopic Mass g/mol
Topological Polar Surface Area125
Heavy Atom Count38
Formal Charge0
Complexity966
Isotope Atom Count0
Defined Atom Stereocenter Count2
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty